Enclomiphene side effects: What to expect and what a prescriber checks

Published enclomiphene trials used daily oral doses of 12.5 mg or 25 mg.^[1] The clearest documented lab change is a rise in estradiol along with testosterone.^[2] The symptoms a prescriber asks about include visual changes, mood shifts, acne, breast tenderness, and headaches. That differs from testosterone therapy, where monitoring centers on hematocrit.^[3] The bigger issue is fit. Enclomiphene was studied in men with secondary hypogonadism, meaning low testosterone with low or inappropriately normal LH,^[2] and guidelines require symptoms plus repeat morning labs before that diagnosis is made.^{[3] [4]}

Key takeaways

• Diagnosis requires both persistent symptoms and biochemical evidence on repeat morning testing. A single low testosterone result is not enough, and LH plus FSH are checked with testosterone to classify primary vs secondary hypogonadism.^{[3] [4]}
• Published enclomiphene trials used 12.5 mg and 25 mg once daily.^[1] Dose changes should rest on symptoms plus repeat labs, not on symptoms alone.
• Enclomiphene can raise testosterone while increasing LH and FSH and preserving sperm counts, which is the main reason it is considered for men who want to maintain fertility.^{[2] [5]}
• With testosterone therapy, the main lab safety issue is a rising hematocrit, so guidelines call for hematocrit monitoring.^[3] In the TRAVERSE trial, published in the New England Journal of Medicine in 2023, testosterone was noninferior to placebo for major cardiovascular events in 5,246 men followed for a mean of 33 months.^[6]
• Before deciding whether enclomiphene is appropriate at all, a prescriber needs repeat morning total testosterone from an accurate assay, LH and FSH, free testosterone by equilibrium dialysis or an accurate formula when total testosterone is borderline or SHBG may be altered, and baseline safety labs such as hematocrit and PSA.^{[3] [4]}

Why enclomiphene side effects happen

Enclomiphene works by stimulating the hypothalamic pituitary testicular axis, not by replacing testosterone from the outside, and that mechanism shapes its side effects.^{[2] [5]} It is a purified trans isomer, separated from its cis partner zuclomiphene, and it acts as an estrogen receptor antagonist.^{[5] [7]} Blocking estrogen feedback at the hypothalamus lifts GnRH signaling, raises pituitary LH and FSH, and prompts the testes to make more testosterone.^{[2] [5]} LH is luteinizing hormone, the brain’s signal to testicular Leydig cells. FSH is follicle stimulating hormone, the signal that supports sperm production.

Because testosterone rises through the body’s own axis, estradiol can rise too.^[2] That is why prescribers ask about acne, oily skin, breast tenderness, headaches, irritability, and visual complaints rather than assuming every hormone side effect looks like a testosterone therapy side effect. According to the Endocrine Society and AUA guidelines, the first step is still diagnosis: symptoms plus repeat morning testosterone, followed by tests such as LH and FSH that identify the cause.^{[3] [4]}

In a 2014 randomized phase II trial in Fertility and Sterility, enclomiphene raised testosterone in men with secondary hypogonadism to levels similar to topical testosterone gel, while also raising LH and FSH and conserving sperm counts.^[2] A smaller 2013 randomized trial of 12 men in The Journal of Sexual Medicine found the same pattern: only the enclomiphene group had higher LH and FSH, and sperm counts rose in all seven men on enclomiphene at 3 months, while the gel did not raise any of five men above 20 million per mL.^[7] That does not make side effects impossible. The side effect profile differs because the mechanism differs.

How a prescriber chooses the dose and monitoring plan

Prescribing enclomiphene starts with confirming that a man has symptomatic hypogonadism, not just a low lab value, and then finding out where the problem starts.^{[3] [4]}

Start with the right diagnosis

Male hypogonadism is a clinical syndrome that requires both symptoms and consistently low testosterone on repeat morning testing with an accurate assay.^{[3] [4]} The European Male Ageing Study, published in the New England Journal of Medicine in 2010, found that late onset hypogonadism was best identified by at least three sexual symptoms, such as poor morning erections, low sexual desire, and erectile dysfunction, together with total testosterone below 11 nmol/L (320 ng/dL) and free testosterone below 220 pmol/L (64 pg/mL).^[8] The Endocrine Society recommends measuring free testosterone by equilibrium dialysis or an accurate formula when total testosterone is near the lower limit of normal or when a condition alters SHBG.^[3] LH and FSH are measured alongside testosterone. High LH with low testosterone points to primary hypogonadism, where the testes themselves are failing. Low or inappropriately normal LH points to secondary hypogonadism, where the signal from the brain is weak.^{[3] [4]} Secondary hypogonadism is the group in which enclomiphene was tested.^{[2] [7]}

Published enclomiphene dosage ranges

Published enclomiphene trials used daily oral doses of 12.5 mg and 25 mg, including trials in obese men with low testosterone.^[1] Enclomiphene is not FDA-approved, so no FDA label standardizes its dosing, and these trial doses are the main reference point.

A prescriber adjusts the dose by weighing symptom response, repeat morning hormone labs, and side effects together. Because estradiol rises along with testosterone on enclomiphene,^[2] a higher dose is not always the answer when testosterone climbs but breast tenderness or other estradiol symptoms appear. Lowering the dose, pausing treatment, or revisiting the diagnosis may fit better.

What bloodwork is checked before treatment

Before treatment, a prescriber needs hormone tests that establish the diagnosis and safety tests that show whether treatment is appropriate at all. According to the 2018 AUA guideline and the Endocrine Society guideline, diagnosis starts with repeat morning total testosterone, and the cause is then sorted out with tests such as LH and FSH, which separate primary from secondary hypogonadism.^{[3] [4]} Depending on the history, the workup may also include free testosterone, estradiol, a CBC, a Comprehensive Metabolic Panel, and prolactin or TSH when pituitary or thyroid disease is suspected.^[3]

Some practices also add vitamin D, PSA from age 40, and insulin in men with a higher BMI. Men often arrive with symptoms that overlap with metabolic dysfunction, erectile problems, poor sleep, or pituitary disease, and a testosterone result alone cannot sort those out.

What bloodwork is checked after treatment starts

After treatment starts, repeat labs show whether the dose is working. In the published trials, testosterone, LH, FSH, and estradiol were remeasured during treatment to track the response.^{[2] [7]} Rechecking after the first month and then at regular intervals lets a prescriber adjust the dose, with prolactin, TSH, and lipid testing added when clinically indicated. The effect also depends on continued use: in the 2013 Journal of Sexual Medicine trial, testosterone fell back to pretreatment values one month after enclomiphene was stopped.^[7]

A CBC stays on the list even though enclomiphene is not testosterone replacement. If treatment ever moves to testosterone, the Endocrine Society treats an elevated hematocrit as a reason not to start and calls for hematocrit monitoring during therapy, so a baseline value is useful.^[3]

Enclomiphene vs testosterone

Enclomiphene vs testosterone is mainly a question of mechanism, fertility goals, and diagnosis.^{[2] [5]} Testosterone therapy fits primary hypogonadism, where the testes cannot respond to stimulation, and secondary hypogonadism that has not responded to stimulation. The Endocrine Society recommends against starting testosterone in men planning fertility in the near term, and in trials testosterone gel did not support sperm counts the way enclomiphene did.^{[2] [3] [7]}

Which conditions change the risk and the right treatment

Primary hypogonadism, functional hypogonadism, pituitary disorders, and baseline prostate or blood count issues can change which treatment is appropriate and what has to be monitored by the clinic you use.^{[3] [4]}

Primary hypogonadism. Low testosterone with clearly elevated LH means the testes are not responding to the signal they already receive.^{[3] [4]} A drug that raises LH further has little to work with in that setting, which points toward testosterone replacement instead.

Secondary or functional hypogonadism. Low testosterone with low or inappropriately normal LH is the pattern enclomiphene was developed for.^[2] Obesity, metabolic syndrome, type 2 diabetes, and some medications can suppress the axis without damaging it, and the Endocrine Society guideline recommends looking for the cause once low testosterone is confirmed.^[3] Enclomiphene has also been tested in obese men with low testosterone.^[1]

Pituitary or thyroid red flags. Prolactin excess and thyroid disease can mimic or worsen low testosterone symptoms. That is why prolactin and TSH are added when the history or baseline labs suggest a central cause that should not be missed.^{[3] [4]}

Prostate and blood count issues. PSA and hematocrit are part of the baseline because the Endocrine Society lists a PSA above 4 ng/mL, or above 3 ng/mL in men at higher risk, and an elevated hematocrit among reasons not to start testosterone therapy without further evaluation.^[3] Testosterone therapy is the treatment most associated with a hematocrit rise, but a baseline value is still useful if the plan changes.

Side effects and lab signals men should watch for

Enclomiphene side effects show up either as changes a man can notice or as lab changes, such as a rise in estradiol, that only repeat testing catches.^[2] The evidence is thin for rare effects. The 2013 Journal of Sexual Medicine trial followed 12 men for 6 months,^[7] while the TRAVERSE testosterone trial followed 5,246 men for a mean of 33 months,^[6] so uncommon enclomiphene side effects are harder to quantify than the better studied risks of testosterone therapy.

• Your vision feels “off,” especially if you notice blur, floaters, light sensitivity, or brief flashes that were not there before. Visual symptoms are a known warning sign with drugs in this class and are a reason to stop and contact the prescriber rather than push through.
• You feel more irritable, more emotionally reactive, or unusually “amped up” after starting. That can happen when testosterone and estradiol rise faster than your symptoms improve.
• You develop new acne, oilier skin, or breakouts across the shoulders, back, or jawline. That is a common androgen response pattern.
• Your nipples feel tender, your chest feels puffy, or you notice water retention. That pattern should trigger an estradiol check.
• You get headaches that cluster around dose days or the first few weeks of treatment. Note when they started and whether the dose changed near the same time.
• Your labs improve but you still feel flat, tired, or sexually disconnected. In the European Male Ageing Study, fatigue and low mood were less specific to low testosterone than sexual symptoms were,^[8] so the dose, the diagnosis, sleep apnea, or depression may need a second look.
• If you are comparing enclomiphene vs testosterone, suppressed sperm production and a rising hematocrit are more characteristic of testosterone therapy than of enclomiphene.^{[1] [3] [7]}

Myth vs fact

Myth: One low testosterone result means you need enclomiphene

Fact: According to the Endocrine Society and AUA guidelines, hypogonadism requires symptoms plus repeat morning testosterone testing. LH and FSH belong in the workup because they show whether the problem is primary or secondary, which directly changes the treatment choice.^{[3] [4]}

Myth: Enclomiphene and testosterone have the same side effects

Fact: They do not. In trials comparing the two, enclomiphene raised LH and FSH and preserved sperm counts, while testosterone gel did not.^{[2] [7]} Testosterone therapy also has a clear association with a rising hematocrit, which is why hematocrit monitoring is central to testosterone care.^[3]

Myth: A higher enclomiphene dosage always works better

Fact: Published trials used 12.5 mg and 25 mg once daily,^[1] and real prescribing is about symptom response plus repeat labs. Because estradiol rises with testosterone on enclomiphene,^[2] more drug can bring more estradiol symptoms without fixing a wrong diagnosis or a nonhormonal cause of fatigue and low libido.

Myth: If you buy enclomiphene online, labs are optional

Fact: Any legitimate online pathway should start with the same diagnostic standards as in person care. That means repeat morning testosterone with LH and FSH to classify the problem. Additional testing such as free testosterone, estradiol, CBC, Comprehensive Metabolic Panel, prolactin, TSH, PSA, or insulin may be used when clinically indicated or as part of a practice’s own workup.^{[3] [4]}

Myth: TRT is always the stronger and therefore better option

Fact: Testosterone therapy is an established treatment for symptomatic hypogonadism, including primary hypogonadism, but guidelines advise against it for men planning fertility in the near term.^{[3] [4]} For men with low or normal LH who want to preserve fertility, enclomiphene raised testosterone while keeping sperm counts up in trials.^{[2] [7]} Mechanism and diagnosis come first.

What to do before you start enclomiphene online

Starting enclomiphene through an online service should follow the same steps as an in person workup.

1. Step 1: Confirm that symptoms and labs match. Get repeat morning testosterone, free testosterone by equilibrium dialysis when total testosterone is borderline or SHBG may be altered, plus LH and FSH so the problem is classified before treatment is discussed.^{[3] [4]}
2. Step 2: Match the treatment to the pattern. If LH is low or normal and symptoms persist, enclomiphene may be a fit. If LH is high with low testosterone, the testes may not be able to respond, and testosterone replacement may be the more appropriate path.^{[2] [3] [4]}
3. Step 3: Recheck and adjust. Use symptom review plus repeat morning labs after the first month and then at regular intervals to decide whether to continue, lower, raise, or stop treatment. If erections or lower urinary tract symptoms are also part of the picture, a combined oral plan that includes tadalafil may make more sense than treating testosterone in isolation.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs you already have, and licensed providers across the U.S. can prescribe enclomiphene or the enclomiphene plus tadalafil tablet when appropriate. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

Bottom line

Enclomiphene raises testosterone by stimulating the body’s own axis, and in trials estradiol rose along with testosterone.^[2] Sperm counts were preserved on enclomiphene in comparisons with testosterone gel,^{[2] [7]} while testosterone therapy is more defined by fertility concerns and hematocrit rise.^[3] Published trials used 12.5 mg or 25 mg daily,^[1] and any adjustment should follow repeat morning labs that confirm the diagnosis and track side effects.

References

1. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117:677-85. PMID: 26496621
2. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102:720-7. PMID: 25044085
3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
4. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200:423-432. PMID: 29601923
5. Rodriguez KM, Pastuszak AW, Lipshultz LI. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opin Pharmacother. 2016;17:1561-7. PMID: 27337642
6. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117. PMID: 37326322
7. Kaminetsky J, Werner M, Fontenot G, et al. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013;10:1628-35. PMID: 23530575
8. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123-35. PMID: 20554979